Abstract
The incidence of graft-versus-host disease (GVHD) after cord blood (CB) transplantation (CBT) is lower than expected given the marked degree of human leukocyte antigen (HLA)-mismatch of CB grafts. While the exact mechanism that underlies this biology remains unclear, it is hypothesized to be due to the low number of mostly immature T-cells infused as part of the graft1,2, and increased tolerance of CB-derived lymphocytes induced by the state of pregnancy. Nevertheless, acute GVHD (aGVHD) is a significant complication of CBT. In contrast, the incidence of chronic GVHD (cGVHD) following CBT is lower than what is observed following matched related or unrelated donor HSC transplantation (HSCT)3-6. This review outlines the guidelines for the prevention and management of acute and chronic GVHD following CBT.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 540-544 |
| Number of pages | 5 |
| Journal | Transplantation and Cellular Therapy |
| Volume | 27 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2021 |
Bibliographical note
Publisher Copyright:© 2021 The American Society for Transplantation and Cellular Therapy
Keywords
- Cord blood transplant
- Graft-versus-host disease
Fingerprint
Dive into the research topics of 'Guidelines for the Prevention and Management of Graft-versus-Host Disease after Cord Blood Transplantation'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS